IVIG Therapy for Autoimmune Necrotizing Myopathy

Clinical Presentation and Indication

The patient has autoimmune necrotizing myopathy with elevated CPK levels, indicating ongoing muscle inflammation despite prior treatment, which meets criteria for IVIG therapy 1
Elevated CPK is a marker of disease activity in inflammatory myopathies and indicates the need for continued immunomodulatory therapy 2
The patient's condition represents Grade 3 myositis, which according to guidelines warrants IVIG therapy when there is inadequate response to corticosteroids 3, 1

The standard dosing for IVIG in inflammatory myopathies is 1-2 g/kg of ideal body weight, typically administered monthly 1
The prescribed 50g of Gammagard Liquid 10% is appropriate based on weight-based dosing recommendations for this condition 1
The scheduled treatment dates follow the appropriate monthly dosing schedule recommended for IVIG therapy in inflammatory myopathies 1

Diphenhydramine 25mg is appropriate as premedication to prevent allergic reactions to IVIG 1
This premedication protocol represents standard practice for IVIG infusion to minimize adverse reactions 1

Regular monitoring of CPK levels is essential to assess treatment response, with decreasing levels indicating effective therapy 2
If symptoms and CPK levels do not improve after 4-6 weeks of IVIG therapy, consideration should be given to adding other immunosuppressants such as methotrexate, azathioprine, or mycophenolate mofetil 3
Patients should be monitored for potential adverse reactions to IVIG, including headache, infusion reactions, renal dysfunction, and aseptic meningitis syndrome 4

Failure to check IgA levels before administering IVIG can lead to severe anaphylactic reactions in IgA-deficient patients 1
IVIG should not be administered immediately before plasmapheresis, as it will be removed 5